The aim of this analysis was to characterize viral resistance in the Phase III, randomized ODIN trial, which demonstrated non-inferiority of once-daily darunavir/ritonavir (DRV/r) 800/100 mg to DRV/r 600/100 mg twice daily, each combined with an optimized background regimen in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening.
Methods
Virological failure (VF) was defined as never achieving or losing confirmed virological suppression after week 12, with patients being classed as ‘never suppressed’ (never achieved HIV-1 RNA<50 copies/ml) or ‘rebounders’ (achieved two consecutive HIV-1 RNA<50 copies/ml but then ≥50 copies/ml). Phenotypes and genotypes of plasma HIV-1 viruses, using population-based sequencing and Antivirogram®, were determined at screening/baseline and on samples from VFs with HIV-1 RNA≥50 copies/ml.
Results
Mean baseline HIV-1 RNA was 4.16 log10 copies/ ml and 53.9% of patients were protease inhibitor (PI)-experienced at enrolment. VF rate was similar in both arms. A similar proportion of virologically failing patients in both arms developed PI RAMs (11.7% versus 9.5%, respectively) or nucleoside reverse transcriptase inhibitor RAMs (6.7% versus 7.1%). One patient with VF (once-daily arm) developed four primary PI mutations, three of which were also DRV RAMs. This patient was also the only VF to lose susceptibility to DRV. Loss of susceptibility to other PIs (once daily 3.4%; twice daily 0%) and nucleoside reverse transcriptase inhibitors (once daily 13.6%; twice daily 9.8%) in VF patients was infrequent and comparable between treatment arms.
Conclusions
These analyses showed once-daily DRV/r 800/100 mg was associated with similar rates of VF and emergence of resistance as DRV/r 600/100 mg twice daily in treatment-experienced patients with no DRV RAMs.
References
1.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Updated 10 January 2011. Accessed 11 September 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2.
MaggioloF., RavasioL., RipamontiD.Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis2005; 40: 158–163.
OrtizR., DeJesusE., KhanlouH.Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS2008; 22: 1389–1397.
5.
OrkinC., DeJesusE., KhanlouH.ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naive HIV-1-infected adults.10th International Congress on Drug Therapy in HIV Infection. 7–11 November 2010, Glasgow, UK. Abstract P3.
6.
CahnP., FourieJ., GrinsztejnB.Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS2011; 25: 929–939.
7.
ClotetB., BellosN., MolinaJ.M.Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet2007; 369: 1169–1178.
8.
KatlamaC., BellosN., GrinsztejnB.POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients.9th International Congress on Drug Therapy in HIV Infection. 9–13 November 2008, Glasgow, UK. Abstract P21.
9.
PozniakA., ArastehK., MolinaJ-MPOWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients.9th International Congress on Drug Therapy in HIV Infection. 9–13 November 2008, Glasgow, UK. Abstract P24.
10.
MadrugaJ.V., BergerD., McMurchieM.Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled Phase III trial. Lancet2007; 370: 49–58.
11.
De MeyerS.M., Spinosa-GuzmanS., VangeneugdenT.J., de BéthuneM.P., MirallesG.D.Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr2008; 49: 179–182.
12.
De La RosaG., PatteryT., PicchioG., LathouwersE., VillacianJ., Van der BorghtK.Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003–2009.10th International Congress on Drug Therapy in HIV Infection. 7–11 November 2010, Glasgow, UK. Abstract P132.
13.
De MeyerS., DierynckI., LathouwersE.Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2.16th International HIV Drug Resistance Workshop. 10–14 June 2008, Sitges, Spain. Abstract 31.
14.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1. Top HIV Med2008; 16: 138–145.
15.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med2010; 18: 156–163.
16.
VandenbrouckeI., Van MarckH., MostmansW.HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res Ther2010; 7: 4.
17.
de MeyerS., VangeneugdenT., Van BaelenB.Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses2008; 24: 379–388.
18.
De MeyerS., LathouwersE., DierynckI.Characterization of virologic failure patients on darunavir/ ritonavir in treatment-experienced patients. AIDS2009; 23: 1829–1840.
19.
LathouwersE., De MeyerS., DierynckI.Virological characterisation of patients failing DRV/r or LPV/r in the ARTEMIS study: 96 week analysis. Antivir Ther2011; 16: 99–108.
20.
De MeyerS., LathouwersE., DierynckI.Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients.9th International Congress on Drug Therapy in HIV Infection. 9–13 November 2008, Glasgow, UK. Abstract 0424.
